Volume 19 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(8): 1303-1305
SUN Wei, WANG Fei, YANG Guang-shu, YU Ying. Clinical efficacy of dapagliflozin in the treatment of type 2 diabetes mellitus[J]. Chinese Journal of General Practice, 2021, 19(8): 1303-1305. doi: 10.16766/j.cnki.issn.1674-4152.002046
Citation: SUN Wei, WANG Fei, YANG Guang-shu, YU Ying. Clinical efficacy of dapagliflozin in the treatment of type 2 diabetes mellitus[J]. Chinese Journal of General Practice, 2021, 19(8): 1303-1305. doi: 10.16766/j.cnki.issn.1674-4152.002046
shu

Clinical efficacy of dapagliflozin in the treatment of type 2 diabetes mellitus

doi: 10.16766/j.cnki.issn.1674-4152.002046
  • 1.

    Department of Endocrinology, Huaibei People's Hospital, Huaibei, Anhui 235000, China

Funds:

 KJ2019A0306

 rj201810

  • Received Date: 2021-07-11
    Available Online: 2022-02-16
    Abstract
  •   Objective  To observe the clinical therapeutic effect, safety and tolerance of dapagliflozin combined with premix insulin in treatment for type 2 diabetes mellitus with poor glucose control.   Methods   Total 60 patients with type 2 diabetes mellitus with poor glycemic control treated with oral insulin aspartate 30 and metformin were treated in Huaibei People's Hospital from January 2019 to March 2020 were divided into 2 groups, 30 cases in each group according to the clinical treatment. The observation group received the treatment of dapagliflozin combined with insulin aspart 30 and metformin, and the control group was only treated with insulin aspart 30 and metformin. Two groups of the patients adjust insulin dose according to the level of plasma glucose. The patient's fasting plasma glucose (FPG), 2-hour postprandial blood glucose (2hPG), hemoglobin A1c (HbA1c), plasma glucose controlling time, insulin doses, presence of hypoglycemic events, weight change and adverse reaction were recorded.   Results   After 12 weeks of treatment, the fasting plasma glucose, 2-hour postprandial blood glucose and hemoglobin A1c in the two groups were lower than before treatment (P < 0.05). Fasting plasma glucose (6.60±0.52) mmol/L, plasma glucose controlling time (6.67±1.60) d, insulin dosage (40.17±7.01) U/d and body mass index (23.41±2.11) in the observation group were lower than the control group (P < 0.05). Two patients in the observation group had hypoglycemia, while eight patients in the control group had hypoglycemia. The incidence of hypoglycemia in the control group was higher than that in the observation group. There was statistical difference between the two groups (P < 0.05).   Conclusion   The clinical efficacy of dapagliflozin combined with premix insulin is significant in the treatment of type 2 diabetes. It has the advantages of weight loss, good safety and tolerance.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志, 2018, 10(1): 4-67. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201804009.htm
    [2]
    CRISMAN M, LUCCHETTA L, LUETHI N, et al. The effect of insulin administration on c-peptide in critically ill patients with type 2 diabetes[J]. Ann Intensive Care, 2017, 7(1): 50. doi: 10.1186/s13613-017-0274-5
    [3]
    胡琛亮, 奚宇, 王玉婵, 等. 对新诊断2型糖尿病患者为期12周多次胰岛素类似物皮下注射强化治疗的疗效观察[J]. 中华全科医学, 2019, 17(10): 1691-1693, 1721. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201910022.htm
    [4]
    SHARMA R, WILKINSON L, VRAZIC H, et al. Comparative efficacy and safety of once-weekly semaglutide and sodium-glucose co-transporter 2 inhibitors (SGLT2) in type 2 diabetic patients inadequately controlled with Misinform chemotherapy[J]. Curr Med Res Opin, 2018, 34(9): 1595-1603. doi: 10.1080/03007995.2018.1476332
    [5]
    ZINMAN B, BHOSEKAR V, BUSCH R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial[J]. Lancet Diabetes Crinoline, 2019, 7(5): 356-367. doi: 10.1016/S2213-8587(19)30066-X
    [6]
    葛均波, 徐永健. 内科学[M]. 9版. 北京: 人民卫生出版社, 2018: 733-734.
    [7]
    刘烈华, 李延兵. 人生难再少, 强化莫失机——2型糖尿病防治策略的思考[J]. 中华糖尿病杂志, 2020, 12(7): 440-444. doi: 10.3760/cma.j.cn115791-20200210-00061
    [8]
    王玉荣, 许晨, 董其娟. 达格列净和西格列汀辅助治疗超重肥胖及胰岛素治疗不佳T2DM患者研究[J]. 现代医药卫生, 2021, 37(2): 279-281. doi: 10.3969/j.issn.1009-5519.2021.02.028
    [9]
    刘建军, 刘静. 糖尿病患者应用胰岛素后致严重高胰岛素血症1例[J]. 中国实用医药, 2018, 13(6): 138-139. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201806087.htm
    [10]
    宋艳东, 李志忠, 张京梅, 等. 钠-葡萄糖共转运蛋白2抑制剂对2型糖尿病患者的心血管保护作用[J]. 中国医药, 2019, 14(11): 1746-1749. doi: 10.3760/j.issn.1673-4777.2019.11.036
    [11]
    CHO Y K, KANG Y M, LEE S E, et al. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis[J]. Diabetes Metab, 2018, 44(5): 393-401. doi: 10.1016/j.diabet.2018.01.011
    [12]
    高芳芳, 张萍, 钟兴, 等. 达格列净对血糖控制不佳的2型糖尿病患者血糖波动的影响[J]. 山东医药, 2020, 60(14): 48-50. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY202014014.htm
    [13]
    陈显英, 符茂雄. 从循证医学角度看致体重降低降糖药物的长期有效性和安全性[J]. 药品评价, 2018, 15(3): 29-33, 64. https://www.cnki.com.cn/Article/CJFDTOTAL-YPPJ201803007.htm
    [14]
    YANG L, ZHANG L, HE H, et al. Efficacious and safety of sodium-glucose co transporter 2 inhibitors in east asians with type 2 diabetes: a systematic review and meta-analysis[J]. Diabetes Ther, 2019, 10(8): 1921-1934. doi: 10.1007/s13300-019-0674-7
    [15]
    ZHANG L, ZHANG M, LV Q G, et al. Efficacy and safety of sodium-glucose co transporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis[J]. Diabetes Res Clin Pract, 2018, 140(7): 295-303.
    [16]
    徐爱花, 黄建胜, 何银辉, 等. 达格列净片治疗2型糖尿病血糖控制不佳患者的疗效与低血糖风险观察[J]. 中华全科医学, 2020, 18(9): 1500-1503, 1526. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202009020.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (142) PDF downloads(7) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return